A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...